ASLAN is a pharmaceutical company that develops novel medicines for global markets. The firm's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. The company is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The firm is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The firm is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
Mr. Carl Firth 2011 'den beri şirketle birlikte olan Aslan Pharmaceuticals Ltd 'in Chief Executive Officer 'ıdır.
ASLN hissesinin fiyat performansı nasıl?
ASLN 'in mevcut fiyatı $0.6 'dir, son işlem günde 14.27% azalmış etti.
Aslan Pharmaceuticals Ltd için ana iş temaları veya sektörler nelerdir?
Aslan Pharmaceuticals Ltd Biotechnology endüstrisine ait ve sektör Health Care 'dir
Aslan Pharmaceuticals Ltd 'in piyasa değerlemesi nedir?
Aslan Pharmaceuticals Ltd 'in mevcut piyasa değerlemesi $1.6M 'dir
Aslan Pharmaceuticals Ltd al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 4 analist Aslan Pharmaceuticals Ltd için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 5 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir